Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
116 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2014', provides an overview of the Post-Traumatic Stress Disorder (PTSD)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Post-Traumatic Stress Disorder (PTSD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Post-Traumatic Stress Disorder (PTSD) Overview 9 Therapeutics Development 10 Pipeline Products for Post-Traumatic Stress Disorder (PTSD) - Overview 10 Pipeline Products for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis 11 Post-Traumatic Stress Disorder (PTSD) - Therapeutics under Development by Companies 12 Post-Traumatic Stress Disorder (PTSD) - Therapeutics under Investigation by Universities/Institutes 14 Post-Traumatic Stress Disorder (PTSD) - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Post-Traumatic Stress Disorder (PTSD) - Products under Development by Companies 19 Post-Traumatic Stress Disorder (PTSD) - Products under Investigation by Universities/Institutes 21 Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development 22 Addex Therapeutics Ltd 22 Azevan Pharmaceuticals, Inc. 23 Catalyst Pharmaceutical Partners, Inc. 24 Humanetics Corporation 25 Intra-Cellular Therapies, Inc. 26 Marinus Pharmaceuticals, Inc. 27 Nanotherapeutics, Inc. 28 Neuralstem, Inc. 29 Neurocrine Biosciences, Inc. 30 NeuroNascent, Inc. 31 Omeros Corporation 32 Otsuka Holdings Co., Ltd. 33 Pfizer Inc. 34 Polleo Pharma Limited 35 Tonix Pharmaceuticals Holding Corp. 36 Vanda Pharmaceuticals Inc. 37 Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment 38 Assessment by Monotherapy Products 38 Assessment by Target 39 Assessment by Mechanism of Action 41 Assessment by Route of Administration 43 Assessment by Molecule Type 45 Drug Profiles 47 7-Keto - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 ADX-71743 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 brexpiprazole - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 CPP-115 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Drug for Post-Traumatic Stress Disorders - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Drugs to Inhibit FAAH for CNS Disorders - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 ganaxolone - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 iloperidone - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 ITI-007 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 NNI-351 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 NSI-189 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 NTC-942 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 PF-04457845 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Rycal - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 S-107 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Small Molecule to Target GPR151 for CNS Diseases - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Small Molecules for BED and PTSD - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Small Molecules for Post-Traumatic Stress Disorder - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Small Molecules to Inhibit mGluR7 For Central Nervous System Disorders - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 SRX-246 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 SRX-251 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 TNX-102 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Vaccine for PTSD and Depression - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 verucerfont - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 vigabatrin - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 ZL-006 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 Post-Traumatic Stress Disorder (PTSD) - Recent Pipeline Updates 89 Post-Traumatic Stress Disorder (PTSD) - Dormant Projects 107 Post-Traumatic Stress Disorder (PTSD) - Discontinued Products 108 Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones 109 Featured News & Press Releases 109 Jun 10, 2014: Tonix Pharmaceuticals Receives IND Clearance From U.S. Food and Drug Administration for TNX-102 SL in Post-Traumatic Stress Disorder 109 Oct 11, 2013: Tonix Pharmaceuticals to Participate in the Women's Healthcare Innovation and Leadership Showcase on October 15, 2013 109 Aug 19, 2013: Tonix Pharmaceuticals Presents Nonclinical Results at the Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome 110 Oct 24, 2012: Tonix Pharma Completes Pre-IND Meeting With FDA For Potential New Treatment For Post-Traumatic Stress Disorder 110 Oct 15, 2012: Indiana University Scientists Discover New Drug For Preventing Post-Traumatic Stress Disorder 111 Aug 30, 2012: Armgo Pharma Announces Publication Of Data Related To New Approach For Treatment Of Stress-Induced Cognitive Disorders 111 May 23, 2012: Nanotherapeutics Initiates Phase II Clinical Trial Of PRX-3140 For Treatment Of Post Traumatic Stress Disorder 112 Jun 20, 2011: Neuralstem On Schedule To Complete Phase Ia Trial Of NSI-189 In Major Depression 113 Apr 21, 2011: Marinus Announces Commencement Of Phase II Trial Of Ganaxolone In Posttraumatic Stress Disorder 113 Apr 07, 2011: Marinus Receives US Patent For Ganaxolone 114 Appendix 115 Methodology 115 Coverage 115 Secondary Research 115 Primary Research 115 Expert Panel Validation 115 Contact Us 116 Disclaimer 116
List of Tables Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H2 2014 10 Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis, H2 2014 11 Number of Products under Development by Companies, H2 2014 13 Number of Products under Investigation by Universities/Institutes, H2 2014 14 Comparative Analysis by Late Stage Development, H2 2014 15 Comparative Analysis by Clinical Stage Development, H2 2014 16 Comparative Analysis by Early Stage Development, H2 2014 17 Comparative Analysis by Unknown Stage Development, H2 2014 18 Products under Development by Companies, H2 2014 19 Products under Investigation by Universities/Institutes, H2 2014 21 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H2 2014 22 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals, Inc., H2 2014 23 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2014 24 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Humanetics Corporation, H2 2014 25 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Intra-Cellular Therapies, Inc., H2 2014 26 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Marinus Pharmaceuticals, Inc., H2 2014 27 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Nanotherapeutics, Inc., H2 2014 28 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neuralstem, Inc., H2 2014 29 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neurocrine Biosciences, Inc., H2 2014 30 Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent, Inc., H2 2014 31 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corporation, H2 2014 32 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 33 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Pfizer Inc., H2 2014 34 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Polleo Pharma Limited, H2 2014 35 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2014 36 Post-Traumatic Stress Disorder (PTSD) - Pipeline by Vanda Pharmaceuticals Inc., H2 2014 37 Assessment by Monotherapy Products, H2 2014 38 Number of Products by Stage and Target, H2 2014 40 Number of Products by Stage and Mechanism of Action, H2 2014 42 Number of Products by Stage and Route of Administration, H2 2014 44 Number of Products by Stage and Molecule Type, H2 2014 46 Post-Traumatic Stress Disorder (PTSD) Therapeutics - Recent Pipeline Updates, H2 2014 89 Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H2 2014 107 Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H2 2014 108
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.